Engineered allogeneic T cells decoupling T-cell-receptor and CD3 signalling enhance the antitumour activity of bispecific antibodies

Authors: Kapetanovic et al.

DOI: 10.1038/s41551-024-01255-x

Central Idea: This study demonstrates a method to engineer allogeneic T cells that are unresponsive to their native target antigen, thereby reducing the risk of graft-versus-host disease (GvHD), while retaining their ability to be activated by bispecific antibodies (biAbs) for cancer immunotherapy. These "Allogeneic-Engineered-Decoupled" (AED) T cells could pave the way for "off-the-shelf" T cell therapies combined with biAbs.

Key Concepts:

• BiAb limitations: Current biAb therapies rely on the patient's own T cells, which are often compromised in ca ...